# Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

> **NCT04146038** · PHASE2 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Decitabine
- **DRUG:** Salsalate
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04146038
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2021-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04146038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04146038, "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04146038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*